Before treatment, we: Safety and personalization are our priorities
Figure 1D presents a quantitative summary of the growth data, showing the average cell counts at the endpoint of the experiment across different PTX concentrations
[4] NICE recommends that semaglutide (Wegovy) should be considered for adults with a BMI of 35 kg/m or more, or between 30 and 34.9 kg/m in the presence of at least one weight-related comorbidity, and who have tried standard care without achieving or maintaining adequate weight loss
The numbers are round, memorable, and hard to get wrong even when you are half asleep on injection day
Posttraumatic stress disorder: does the gut microbiome hold the key
It's just insomnia GLP-1s disrupt sleep through multiple biological pathways Clinical studies show that GLP-1 receptors in the dorsomedial hypothalamus directly influence circadian rhythm regulation